This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Third Affiliated Hospital, Third Military Medical University. Active years: 2017.
Company Filing History:
Years Active: 2017
Title: Innovations of Chunyu Zeng in Myocardial Ischemia Reperfusion
Introduction
Chunyu Zeng is an accomplished inventor based in Chongqing, China. He has made significant contributions to the field of medical science, particularly in the area of myocardial ischemia reperfusion injuries. His innovative work focuses on the application of irisin, a protein that has shown promise in reducing the adverse effects associated with myocardial ischemia.
Latest Patents
Chunyu Zeng holds a patent titled "Application of irisin in myocardial ischemia reperfusion." This invention discloses the use of irisin in the preparation of drugs aimed at preventing myocardial ischemia reperfusion injuries. Experimental results indicate that irisin can effectively decrease the myocardial infarction area caused by ischemia reperfusion. It also reduces the increase of various myocardial enzyme markers, such as lactate dehydrogenase (LDH), troponin (cTnI), and creatine kinase (CK), which are typically elevated during ischemia reperfusion. Furthermore, irisin helps mitigate inflammatory responses, myocardial apoptosis, and oxidative stress, promoting nuclear translocation of peroxisome proliferator-activated receptor γ while inhibiting nuclear transcription factor NF-κB. This multifaceted approach leads to a decrease in myocardial structural injuries and load increases caused by ischemia reperfusion, highlighting the clinical significance of irisin in treating myocardial ischemia.
Career Highlights
Chunyu Zeng is affiliated with the Third Affiliated Hospital of the Third Military Medical University. His research and innovations have garnered attention in the medical community, particularly for their potential to improve treatment outcomes for patients suffering from myocardial ischemia.
Collaborations
Chunyu Zeng has collaborated with notable colleagues, including Yu Han and Zhen Wang, who contribute to his research endeavors. Their combined expertise enhances the impact of their work in the field of medical science.
Conclusion
Chunyu Zeng's innovative research on irisin presents a promising avenue for preventing and treating myocardial ischemia reperfusion injuries. His contributions are poised to have a significant impact on clinical practices and patient care in the future.